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Abstract
Background: Contrast-induced nephropathy is the leading cause of in-hospital acute renal failure.
This side effect of contrast agents leads to increased morbidity, mortality, and health costs.
Ensuring adequate hydration prior to contrast exposure is highly effective at preventing this
complication, although the optimal hydration strategy to prevent contrast-induced nephropathy
still remains an unresolved issue. Former meta-analyses and several recent studies have shown
conflicting results regarding the protective effect of sodium bicarbonate. The objective of this study
was to assess the effectiveness of normal saline versus sodium bicarbonate for prevention of
contrast-induced nephropathy.
Methods: The study searched MEDLINE, EMBASE, Cochrane databases, International
Pharmaceutical Abstracts database, ISI Web of Science (until 15 December 2008), and conference
proceedings for randomized controlled trials that compared normal saline with sodium
bicarbonate-based hydration regimen regarding contrast-induced nephropathy. Random-effects
models were used to calculate summary odds ratios.
Results: A total of 17 trials including 2,633 subjects were pooled. Pre-procedural hydration with
sodium bicarbonate was associated with a significant decrease in the rate of contrast-induced
nephropathy (odds ratios 0.52; 95% confidence interval 0.34–0.80, P = 0.003). Number needed to
treat to prevent one case of contrast-induced nephropathy was 16 (95% confidence interval 10–
34). No significant differences in the rates of post-procedure hemodialysis (P = 0.20) or death (P =
0.53) was observed.
Conclusion: Sodium bicarbonate-based hydration was found to be superior to normal saline in
prevention of contrast-induced nephropathy in this updated meta-analysis.
Background
Contrast agents are administered to millions of proce-
dures annually worldwide. In the USA and Europe, con-
trast-induced nephropathy (CIN) is the third leading
cause of acute renal failure in hospitalized patients,
accounting for about 10% of hospital-acquired renal fail-
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gains importance with the growing awareness that even
gadolinium-based agents are not harmless and may
induce renal damage [2].
Two mechanisms have been hypothesized to be responsi-
ble for CIN development: contrast media-triggered vaso-
constriction and development of oxidative stress, that is,
intrarenal accumulation of reactive oxygen species. One
major underlying hypothesis for application of sodium
bicarbonate (NaHCO3) is that the alkalinization of tubu-
lar fluid diminishes the production of free oxygen radicals
[3,4]. Pretreatment with sodium bicarbonate is more pro-
tective than sodium chloride in animal models of acute
ischemic renal failure [5].
Previous meta-analyses have shown a significant benefit
for NaHCO3 in comparison to normal saline (NS) infu-
sion [6,7], although they highlighted the possibility of
publication bias. Two trials published thereafter did not
show an advantage of NaHCO3 [8,9], while multiple
smaller studies have published preliminary but rather
contradictory results [10,11]. A recent retrospective study
suggested even possible harm of NaHCO3 [12]. Given
these conflicting results, an updated meta-analysis is
meaningful. The purpose of this study was to evaluate the
current published and unpublished data regarding the use
of NaHCO3 versus NS as pre-procedural hydration for the
prevention of CIN.
Methods
We searched PubMed, MEDLINE, the Cochrane Central
Register of Controlled Trials, International Pharmaceuti-
cal Abstracts database, and ISI Web of Science and google
scholar from 1990 through to 15 December 2008. In
addition, abstract lists and conference proceedings from
the 2007 and 2008 scientific meetings of the American
College of Cardiology, the European Society of Cardiol-
ogy, the Transcatheter Cardiovascular Therapeutics, the
American Heart Association, the American Society of
Nephrology, the European Renal Association, the annual
meeting of the Radiology Society of North America
Annual, and the World Congress of Cardiology were
searched. We also considered published review articles,
editorials, and internet-based sources of information
(http://www.tctmd.com, http://www.theheart.org) to
assess for potential information on studies of interest.
Medical subject headings and keyword searches included
the terms 'contrast nephropathy', 'sodium bicarbonate',
'saline infusion', 'radiocontrast', and 'renal failure'. Refer-
ence lists of selected articles were reviewed for other
potentially relevant citations. Authors of selected studies
were contacted to obtain further information.
Study selection
In a two-step selection process, two investigators (HSG
and PM) independently reviewed the titles and abstracts
of all citations to identify all potentially relevant studies.
In a second step, the corresponding publications were
reviewed in full text by the same two investigators to
assess if studies met the following inclusion criteria: direct
comparison of NaHCO3 versus pre-hydration with NS,
randomized controlled trial (RCT), and CIN as primary
endpoint based on laboratory testing (Figure 1). Review-
ers were not blinded to study authors or outcomes. Final
inclusion of studies was based on the agreement of both
reviewers. Two studies were excluded because they were
either retrospective [13] or because they randomized
patients to NS + N-acetyl cysteine (NAC) versus NaHCO3
only [14].
Data extraction and quality assessment
Two reviewers (PM and UT) extracted relevant informa-
tion from the articles including baseline clinical character-
istics of the study population, laboratory data, baseline
creatinine, amount of NS infusion in the control group
(total and before contrast administration), type of con-
trast, average contrast volume and data on primary (CIN)
and secondary outcomes, such as mortality, need for
hemodialysis (HD). CIN was defined differently by each
study, but most described it as an absolute or relative
increase in serum creatinine. Seven studies defined CIN as
a rise in serum creatinine by 25% or more within 2 to 5
days of contrast exposure [15-21]. Two studies regarded
an absolute increase of creatinine of 0.5 mg/dl (= 44
μmol/liter) as their primary definition of CIN [9,22],
whereas six authors used a composite definition of either
Flow chart depicting outline of the search and selection strat-egyigure 1
Flow chart depicting outline of the search and selec-
tion strategy. NS = normal saline; NaHCO3 = sodium 
bicarbonate; NAC = N-acetylcysteine. *The study of Schmidt 
et al. [13] was not prospective. †Shavit et al. randomized 
patients to NS + N-acetylcysteine versus NaHCO3.[14]
Figure 1
Stage 1: Review of title 
and abstract
Stage 2: Full text review/ 
contacting study authors
184 potentially relevant 
studies identified
19 studies evaluation effects of NS 
vs. NaHCO3 on contrast-induced
nephropathy
Excluded
Not prospective (n=1*)
Using NAC only in one arm (n=1†)
Excluded
Not a comparison of NS versus NaHCO3
n=165
17 studies evaluation effects of NS 
vs. SB on contrast-induced
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of 0.5 mg/dl [8,11,23-26]. One study [27] used change in
glomerular filtration rate as the primary endpoint and
change in creatinine as a secondary definition for CIN and
one abstract [10] did not mention the CIN definition. For
each study we used the corresponding predefined primary
endpoint. We assessed trial quality by evaluating specific
criteria (concealment of allocation during randomization,
intention-to-treat analysis, and blinded assessment of
outcome measures), but did not use a quality score in
regard to the limitations inherent in such an approach
[28].
Data synthesis and analysis
Data from all the selected studies were combined to esti-
mate the pooled odds ratio (OR) of effect sizes for NS
compared with NaHCO3 using a random-effects model.
All analyses were performed on an intention-to-treat
basis. Continuity correction was used when an event did
not occur in one group [29]. Significant between-study
heterogeneity was expected regarding study populations,
therefore a random-effects model was used to produce
Table 1: Incidence of contrast-induced nephropathy in treatment 
arms.
Study CIN incidence NaHCO3 (%) CIN incidence NS (%)
Merten 1.7 13.6
Hengel 2.6 12.1
REMEDIAL 1.9 9.9
RENO 1.8 21.8
Masuda 6.7 34.5
Ozcan 4.5 13.6
Shaikh 8.8 11.8
Kim 17.9 18.2
Chen 1.8 14.0
Heguilen 11.1 11.1
Saidin 31.0 14.3
Brar 13.3 14.5
Maioli 10.0 11.5
REINFORCE 4.2 2.7
Malpica 15.8 21.7
Tamura 1.4 12.5
Lin 13.3 16.7
CIN = contrast-induced nephropathy; NaHCO3 = sodium 
bicarbonate; NS = normal saline.
The Forest plot of odds ratios of contrast-induced nephropathyFigure 2
The Forest plot of odds ratios of contrast-induced nephropathy. Sizes of data markers are proportional to the weight 
of each study in the meta-analysis. Studies are stratified by year of presentation and/or publication. Horizontal bars, 95% confi-
dence interval. NaHCO3 = sodium bicarbonate; NS = normal saline.Page 3 of 11
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(CI). We evaluated the presence of heterogeneity across
trials with the Q and I2 statistics, with an I2 value > 50%
indicating at least moderate statistical heterogeneity. To
assess the effect of individual studies on the summary esti-
mate of effect, we did an influence analysis, in which the
pooled estimates were recalculated by omitting one study
at a time. We assessed publication bias visually (funnel
plot) and by formal tests (rank order correlation [30] and
Egger's test of intercept [31]). A Funnel plot depicts the
effect estimates from each trial against study sample size
or precision. In absence of publication bias, this plot
should appear approximately symmetrical. The Funnel
plot is based on the fact that large trials can estimate
effects more precisely while smaller trials show wider scat-
tering. A formal measure of Funnel plot asymmetry is the
Egger test. It is a linear regression of normalized effects
(effect divided by its standard error (SE)) against precision
(reciprocal SE of the effect). Very small studies have a
larger SE and, consecutively, a normalized effect and a
precision that is close to zero. Therefore, the intercept of
the regression comes close to zero; if it significantly differs
from zero, this indicates systematic deviance of the effect
of small studies (small study effect and/or bias, for exam-
ple, due to publication bias).
We also calculated fail-safe N (that is, the number of stud-
ies required to nullify the significant differences in CIN
between the two groups) using Rosenberg's and Orwin's
method [32,33]. As there was a suggestion of publication
bias, Duval and Tweedie's [34] Trim and Fill method was
used to calculate imputed OR for CIN. Exploratory meta-
regression based on a mixed-effect model was performed
to estimate the extent to which selected covariates that
potentially influence risk for CIN could explain the
observed heterogeneity of the NaHCO3 effect (average age
of patients, baseline creatinine, volume of contrast
medium used, prevalence of diabetic patients in the study,
and amount of NS infusion before contrast administra-
tion in the control group). Stratified analysis was per-
formed to assess the effect of NaHCO3-based hydration in
select groups (patients treated with low osmolar versus
iso-osmolar contrast, and those undergoing elective ver-
sus emergent procedures) and to assess impact of pub-
lished versus unpublished studies. All analyses were
performed using Comprehensive Meta-Analysis software,
The Forest plot of odds ratios of contrast-induced nephropathyFigure 3
The Forest plot of odds ratios of contrast-induced nephropathy. This is stratified by studies with elective procedures 
versus those including only emergency procedures. Sizes of data markers are proportional to the weight of each study in the 
meta-analysis. Horizontal bars, 95% confidence interval.Page 4 of 11
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sion 1.7 [35].
Results
A total of 184 articles were reviewed, and 17 studies satis-
fied the predetermined inclusion criteria (Figure 1) [8-
11,15-27]. Eight trials have been published in the peer-
reviewed literature whereas another nine studies are as yet
unpublished but were presented at scientific meetings
(that is, Transcatheter Therapeutics meeting, American
Heart Association meeting, American Society of Nephrol-
ogy meeting, World Congress of Cardiology, or Canadian
Cardiovascular Congress). Further information on these
unpublished trials was obtained from the study authors
where possible. One study randomized patients to three
arms: NaHCO3, NS, or NS and NAC. From this trial, we
used data only from the NaHCO3 and NS arms and
excluded the patients randomized to the NS and NAC arm
[25]. Data from studies using a 2 × 2 factorial-design test-
ing the influence of NAC and the effect of NaHCO3 were
used by pooling patients from the NaHCO3 and NS arms
(with or without NAC) [18,26]. Additional file 1 summa-
rizes the characteristics of the 17 trials, including a total of
2,633 subjects.
Primary endpoint
CIN occurred in a total of 109 patients in the 1,327
patients of the NaHCO3 arms (range 1.4% to 31.0%)
compared with 175 such events in the 1,306 subjects
treated with NS (range 2.7% to 34.5%) (Table 1). The
summary OR was 0.52 (95% CI 0.34–0.81, P < 0.004)
(Figure 2) in favor of NaHCO3. The number needed to
treat to prevent one CIN was 16 (95% CI 10–34).
There was moderate heterogeneity across studies regard-
ing clinical patient characteristics and protocols, and also
formal tests (I2 = 48.0; Q = 30.6; P value = 0.015).
Stratified analyses suggested a more pronounced effect of
NaHCO3 in the two trials including exclusively patients
undergoing emergency procedures [22,24] (OR 0.10; 95%
CI 0.02–0.42; P = 0.002) compared with patients under-
going elective procedures (OR 0.63; 95% CI 0.43–0.92; P
= 0.017) (Figure 3). Similarly, stratified analysis by the
type of contrast medium used suggested lower odds of
CIN with NaHCO3 in studies using low-osmolar contrast
media [11,16,19,20,22-25,27] (OR 0.29; 95% CI 0.15–
0.57) compared with those using the iso-osmolar agent
iodixanol [8,9,15,18] (OR 0.73; 95% CI 0.32–1.64, P =
0.441) (Figure 4).
Forest plot of stratified analysis by studies using iso-osmolar (iodixanol) versus low-osmolar contrast mediaigure 4
Forest plot of stratified analysis by studies using iso-osmolar (iodixanol) versus low-osmolar contrast media. 
Sizes of data markers are proportional to the weight of each study in the meta-analysis. Horizontal bars, 95% confidence inter-
val.Page 5 of 11
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cant association between the reduction in CIN with
NaHCO3 and any of the baseline variables that were tested
(baseline creatinine, NAC use, proportion of patients with
diabetes, contrast volume). The eight published trials
showed a stronger overall benefit of NaHCO3 (OR 0.4;
95% CI 0.21–0.76, P = 0.005) compared with the nine
unpublished studies (OR 0.64; 95% CI 0.34–1.21, P =
0.168) (Figure 5). Furthermore within the published tri-
als, those stopped early [20,24], demonstrated a much
greater reduction in risk of CIN with NaHCO3 (OR 0.12;
95% CI 0.03–0.56, P = 0.007) compared with trials that
completed enrolment as planned (OR 0.53; 95% CI 0.28–
1.0; P = 0.051). After exclusion of those two trials, the
overall OR based on all other studies was 0.60 (95% CI
0.40–0.91; P = 0.016).
The cumulative analysis illustrates the time-course of the
OR when performing a meta-analysis after each new study
in a chronologic order (Figure 6). This suggests that the
initial trials were more likely to show dramatic reduction
in CIN with NaHCO3 but subsequent trials have demon-
strated more modest benefits.
None of the studies influenced the results to an extent that
the conclusion would have changed; the sensitivity analy-
sis omitting one study at a time consistently showed an
overall benefit of NaHCO3 compared with NS (Figure 7).
Assessment of publication bias using a funnel plot indi-
cated slight asymmetry (Figure 8), and this was confirmed
on formal testing (rank order correlation or Kendall τ of -
0.324, one-tailed P value of 0.038, two-tailed P = 0.077,
and Egger's test intercept of -1.71, 95% CI of -3.02 to -0.40
with one-tailed P value of 0.007, two-tailed P = 0.014).
These tests suggest that the results of this meta-analysis
were influenced by a larger treatment effect seen in
smaller studies.
The Trim and Fill method was used to calculate a treat-
ment effect based on imputed estimated unpublished
studies. The imputed OR for CIN using the random-effects
model was 0.62 (95% CI 0.40–0.97). The classic fail-safe
N was 67, suggesting that 67 additional negative studies
would be needed to negate the results of our meta-analy-
sis. A much more conservative variant of this method, the
Orwin's fail-safe N, assumes that unpublished or future
The Forest plot of odds ratios of contrast-induced nephropathy stratified by publication statusFigure 5
The Forest plot of odds ratios of contrast-induced nephropathy stratified by publication status. Sizes of data 
markers are proportional to the weight of each study in the meta-analysis. Horizontal bars, 95% confidence interval.Page 6 of 11
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NaHCO3. Under the very conservative assumption of a
mean OR of 2.7 in unpublished studies (as observed in
the included trial with the most extreme result [21]), eight
such trials would be necessary to nullify the overall bene-
ficial effect of NaHCO3.
Secondary endpoints
Need for dialysis
The need for HD was reported in 12 studies (N = 2,011),
in five of these, there was no HD event in either group
[8,16,19,20,23]. Overall, 6 out of 934 patients treated
with NaHCO3 underwent HD (range 0% to 3.3%) com-
pared with 12 out of the 927 patients treated with NS
(range 0% to 10.3%). This difference was not statistically
significant (OR 0.53; 95% CI 0.20–1.41, P = 0.20).
Mortality
Data for mortality were available from seven studies (N =
1,334). In three studies, no death was observed in either
group [11,19,23]. There were a total of eight deaths in the
886 patients treated with NaHCO3 (range 0% to 1.8%)
and 12 in the 666 patients treated with NS (range 0% to
7.3%). The overall-mortality risk was not significantly dif-
ferent between the two treatment groups (OR 0.74; 95%
CI 0.29–1.9, P = 0.53).
Discussion
In this meta-analysis of 17 RCTs including 2,633 patients,
pre-procedural hydration with NaHCO3 reduced the inci-
dence of CIN compared with hydration with NS. Our
findings thus corroborate and extend the prior meta-anal-
ysis in the field. Our findings were based on a larger
number of trials, include a much larger patient popula-
tion and adjusted for publication bias by including multi-
ple unpublished studies.
Although CIN is generally limited to a transient decline of
renal function, it can not be regarded as a benign compli-
cation. Some degree of residual renal impairment has
Cumulative analysis of contrast-induced nephropathyFigure 6
Cumulative analysis of contrast-induced nephropathy. This figure depicts the summary odds ratios of all trials pub-
lished (in the literature or as an abstract) up to a time point in chronologic order. The odds ratios increase over time illustrat-
ing that earlier trials found more pronounced effects of sodium bicarbonate than subsequent studies, while the confidence 
intervals have narrowed suggesting greater reliability of the effect estimate. Horizontal bars, 95% confidence interval.Page 7 of 11
(page number not for citation purposes)
BMC Medicine 2009, 7:23 http://www.biomedcentral.com/1741-7015/7/23been reported in as many as 30% of those affected by CIN
[36]. In an observational study of patients undergoing
percutaneous coronary intervention, dialysis was started
in 0.8%; persistent renal failure requiring permanent dial-
ysis developed in 13% of these patients [37]; in patients
with diabetes and severe renal failure the rate of dialysis
was even higher [38]. CIN is associated with a prolonged
hospital stay and corresponding additional costs [8,17],
and it portends a high morbidity and an increased in-hos-
pital and long-term mortality [39-43]. Acute renal insuffi-
ciency leads to increased myocardial oxygen consumption
and impaired vascular function in dogs [44] and it is plau-
sible that similar mechanisms may be applicable in
humans.
However, this diminished risk for CIN seems not to trans-
late into a decreased incidence of death or need for HD in
this current meta-analysis. A similar phenomenon has
also been reported in studies evaluating NAC [45]. Several
reasons may account for this disconnection between CIN
and need for renal replacement therapy or mortality. The
patient population enrolled in these studies was generally
young and at low risk of adverse events, and very few stud-
ies provide long-term follow-up data. The incidence of
mortality and need for HD was low in general. Given such
low event rates, even a pooled analysis is underpowered to
detect a significant difference. Furthermore, it is possible
that the definitions of CIN used in these studies are too
sensitive regarding the prediction of adverse outcome.
Finally, contrast media may impair tubular creatinine
excretion, which could lead to an underestimation of the
renal function when using creatinine as a surrogate [46].
Importantly, while not significant statistically, the inci-
dence of both death and need for renal replacement ther-
apy was lower in the NaHCO3 arm.
While the overall results of the meta-analysis and the
imputed OR favors use of NaHCO3, possible reasons for
Forest plot of odds ratios illustrating the influence of single trials on the overall analysisigure 7
Forest plot of odds ratios illustrating the influence of single trials on the overall analysis. Each row represents an 
overall estimate of odds ratios when omitting one study (left column represents name of omitted study). The lowest row 
shows the overall odds ratio when all studies are included. No particular study relevantly influences the overall odds ratio. 
Horizontal bars, 95% confidence interval. NaHCO3 = sodium bicarbonate; NS = normal saline.Page 8 of 11
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and the study settings were rather variable. Stratified anal-
yses revealed differences between NaHCO3 effects in
emergency and elective cases as one potential reason for
the heterogeneity. Interestingly, the benefit of NaHCO3
was less prominent in patients treated with iso-osmolar
contrast than in those treated with other contrast agents.
Recent studies suggest that iodixanol may be less nephro-
toxic compared with some (but not all) low molecular
weight contrast agents and further studies are warranted
to assess the interaction between the type of contrast agent
used and the hydration strategy. These post-hoc analyses
(meta-regressions, subset analyses) must be considered
exploratory and hypothesis generating since they are
based on a small number of trials and no adjustment for
multiple comparisons was made.
The presented overall benefit of NaHCO3 may also be
slightly overestimated by the two trials that were stopped
early (both because of an overwhelming beneficial effect
in the treatment group). Early stopping is controversial
and it can lead to an overestimation of a treatment effect
[47]. However, the early stopped trials are rather small,
and their overall influence therefore limited. Even after
exclusion of these two studies, the overall benefit of
NaHCO3 persists.
The importance of publication bias in meta-analysis in
general and in this field in particular has been highlighted
in the past. The overall magnitude of CIN reduction was
clearly greater in published studies compared with
unpublished studies. The strength of this study is the
inclusion of all available unpublished data and therefore
represents the most robust analysis in this field so far.
However, even after a comprehensive search for, and
inclusion of these unpublished studies, formal testing
indicates a likelihood of more unpublished data. Based
on statistical estimations, the number and overall effect of
unpublished data are probably limited. The treatment
effect based on imputed estimated unpublished studies
still supports superiority of NaHCO3 (OR 0.62; 95% CI
0.40–0.97). The use of NaHCO3 is likely associated with a
reduction in the incidence of CIN, which may be some-
what overestimated by unpublished studies.
On the other hand, the inclusion of many unpublished
studies to overcome the problem of publication bias,
introduces the possibility of including lower-quality data
that has not undergone robust peer review. However,
these trials have all been presented at scientific meetings,
published in an abstract format and have undergone a
limited peer-review.
While most randomized data suggest either a lower risk of
CIN with NaHCO3 or no difference compared with NS, a
large observational study from the Mayo Clinic has raised
the possibility of potential harm with this strategy. In a
retrospective study of 7,911 patients encompassing
11,516 cases of contrast exposure, the risk of CIN among
patients treated with NaHCO3 was significantly increased
compared with the untreated group (OR 3.0, P < 0.05)
[12]. Only a small proportion of patients (489 out of
7,977) were pre-treated with NaHCO3 and the extreme
results of this study in contrast to the randomized data
suggest that the conclusions may be driven by unrecog-
nized confounders. It is reassuring that despite multiple
trials performed in various countries, none has demon-
strated superiority of saline-based hydration and the over-
all odds of mortality and need for renal replacement
therapy albeit exceedingly low overall, are lower in the
NaHCO3 arm. The cumulative analysis further supports
this conclusion, at no particular time point since the first
publication of Merten et al. [20], the OR pointed towards
an inferiority of NaHCO3. However, this also illustrates
the fact that the effect of NaHCO3 probably was signifi-
cantly overestimated at first and the inclusion of the
recent studies seems to be leading us closer to a more
accurate estimate of effect size.
It remains unclear whether there is a dose effect and
whether alkalinization is the underlying beneficial mech-
Funnel plot of contrast-induced nephropathy (with estimated unpub ished studies)ig re 8
Funnel plot of contrast-induced nephropathy (with 
estimated unpublished studies). Trials are depicted by 
circles with the random-effects log odds ratio shown along 
the horizontal axis and precision in estimating this effect 
(reciprocal standard error) along the vertical axis. The Trim 
and Fill method was used to calculate the true center of the 
funnel (indicated by the vertical line) after filling in estimates 
of unpublished studies (depicted with black dots). The empty 
diamond indicates the original confidence intervals of the log 
odds ratio; the black diamond indicates the corresponding 
values when the additional imputed studies are also consid-
ered.Page 9 of 11
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(pH urine or blood) [11,15,19,20,22,24]. All but one
found a significant increase in pH with exception of Lin et
al. [19], which in fact was the only one among them not
to find a benefit of NaHCO3. Therefore, it could be
hypothesized that NaHCO3 should be dosed to achieve
urinary alkalinization. Promisingly, the study of Tamura
et al. [11] indicates that even a single bolus of NaHCO3
administered just prior to contrast administration may be
effective and such a protocol could be easily used in most
healthcare settings. The efficacy of this approach, how-
ever, needs validation in larger studies before it can be rec-
ommended for widespread use.
Conclusion
Our meta-analysis suggested a significant benefit of using
NaHCO3-based hydration for prophylaxis of CIN
although the magnitude of the benefit may have been
overestimated by earlier studies. However, the lack of any
study to date showing superiority of saline-based hydra-
tion suggests that NaHCO3-based hydration should be
considered the optimal hydration in high-risk patients
undergoing exposure to iodinated contrast.
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